Print Digg


Lutein Antioxidant Supplement Trial (LAST): The most requested nutrient study at the Biosyntrx booth - ASCRS 2004

Friday, May 07, 2004

The Veterans LAST study (Lutein Antioxidant Supplementation Trial): Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration.

Methods:  The study was a prospective, 12-month, randomized, double-masked, placebo-controlled trial conducted at an urban Midwestern Veterans Administration Hospital. Ninety patients with atrophic ARMD were referred by ophthalmologists at two Chicago-area veterans medical facilities. Patients in Group 1 received 10 mg of lutein (L):  Group 2 received 10 mg of lutein plus an antioxidant/vitamin/mineral broad spectrum supplementation formula (L/A); and Group 3 received a placebo (P) over a 12 month period.

Results:  In Groups 1(lutein) and 2 (lutein and broad spectrum multiple), mean eye macular pigment optical density increased approximately 0.09 log units from baseline, Snellen equivalent visual acuity improved 5.4 letters and 3.5 letters for groups 1 and 2, and contrast sensitivity improved in both groups of treated patients. There was a net subjective improvement in Amsler grid in Group 1. VFQ-14 questionnaires concerning subjective glare recovery were significant at 4 months for Group 2. Patients who received the placebo (Group 3) had no significant changes or improvements in any of the measured findings.
Ellen Troyer, MT MA - Biosyntrx Chief Research Officer
Spencer Thornton, MD - Biosyntrx President.


We are very pleased to announce the addition of Stuart Richer, OD, PhD, FAAO,  to our Biosyntrx scientific advisory board.  Dr. Richer was the principle investigator of the LAST study, the first US randomized double masked placebo controlled clinical trial of lutein and visual function.


Clinical references available in the Biosyntrx office.